Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Profiting from Protection: The Power of Permission-Based Partner Programs

(Click image to play podcast) Savvy investors know that lot of smart money is now funnelling into forward-thinking companies that are fulfilling an immediate need to provide real world solutions to identity fraud and creating value through data validation. ...
Dave Jackson | August 28, 2020 |

Acceleration of COVID-19 Vaccine Programs Could Benefit U.S. Biotech

The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report. In a May 8 research note, H.C. Wainwright & Co. analyst Ram Selvaraju wrote that the efforts being made in general to accelerate deve...
Streetwise Reports | May 14, 2020 |

Bringing Hope to People Living with Neurodegenerative Diseases

Alpha Cognition Inc. ( TSX-V.ACOG , OTCMKTS: ACOGF , Forum ) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases. Stockhouse Media’s Dave Jackson caught up recently with Company CE...
Dave Jackson | October 20, 2021 |

Oncology Vaccine Developer's Lead Programs 'On Track or Better'

The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. In a May 13 research note, BTIG analyst Thomas Shrader reported that Gritstone Oncology Inc.'s (GRTS:NASDAQ) lead clinical programs, GRANITE and SL...
Streetwise Reports | May 27, 2019 |

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

Shares of Moderna Inc. traded up double-digits today as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. This morning clinical-stage biotechnology company Mode...
Streetwise Reports | September 13, 2019 |

Alianza Minerals Raises C$750,000, Signs LOI with Coeur, Starts Exploration Programs

The Critical Investor provides an update on recent developments with an explorer that has projects in the Yukon and Nevada. Haldane project Although Alianza Minerals Ltd. (ANZ:TSX.V) had to wait for better weather until exploration pro...
Streetwise Reports | July 2, 2019 |

A New Frontier in Psychedelic Therapeutics

Cybin X Kernel "A New Frontier in Psychedelic Therapeutics" About the partnership: Cybin Corporation ( N.CYBN , Forum ) will leverage Kernel’s Flow to quantify brain activity during psychedelic experiences in re...
Featured Submission | January 11, 2021 |

An Emerging Medical Market Play with Great Opportunity

(Image via Bioasis Technologies Inc.) Biopharmaceutical Company Bioasis Technologies Inc. ( TSX-V: BTI , OTCQB: BIOAF , Forum ) is developing its proprietary xB 3TM platform technology to deliver therapeutics across the blood brain barrier (BBB) and int...
Stockhouse Editorial | July 28, 2020 |

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

Galapagos announced that Gilead Sciences has agreed to pay $3.95 billion for a 10-year partnership and licensing deal and will invest an additional $1.1 billion in newly issued shares of the company. Galapagos NV (GLPG:NASDAQ; GLPG:BSE) ADR shares opened up over 1...
Streetwise Reports | July 16, 2019 |

Bond sell-off is due to become more serious

With my indicators on a sell signal for bonds since August 16, I have been warning about bonds being overbought and in danger of rolling over into a serious correction for several months. And indeed, the 20-year U.S. Treasury bond has already lost 11% of its value just since...
Sy Harding | January 7, 2013 |
1 2 3 4 5 6 7 8 9 10 ...